SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (177)3/5/2002 5:55:48 PM
From: rkrw  Respond to of 508
 
What about from a clinical perspective?
They indicated they plan to run a infergen/actimmune combo trial. An amphotec/actimmune trial I believe is underway.

They did inlicense a drug for CF which fits into their pulmonary efforts.

I'm not entirely sure how much marketing synergy matters here as each product can be handled with small, focused niche sales force. In other words, this is no Sepracor :-)

What matter most is running successful trials that pass fda muster. FDA rejections or failed trials will cost a lot more than product disconnect :-)



To: Biomaven who wrote (177)3/5/2002 6:26:24 PM
From: sso  Read Replies (1) | Respond to of 508
 
Hi,

I actually think they have done a pretty good job with sales/marketing Vs pipeline.

amphotec and infergen are hospital drugs and so will be oritavancin. No different than what a hospital rep does in big Pharma.

actimune is a pulmonary office call.

There will be two sales forces I think.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News